Organon Inkomsten in het verleden

Verleden criteriumcontroles 4/6

De winst van Organon is gedaald met een gemiddeld jaarlijks percentage van -29.7%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 1.2%. De inkomsten zijn daalde met een gemiddeld percentage van 2.4% per jaar. Het rendement op het eigen vermogen Organon bedraagt 263.9% en de nettomarge bedraagt 20.3%.

Belangrijke informatie

-29.7%

Groei van de winst

-30.0%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	-2.4%
Rendement op eigen vermogen	263.9%
Nettomarge	20.3%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

May 10

Recent updates

Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)

Nov 13

The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 04

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Sep 19

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

May 29

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

May 10

Four Reasons Why Organon Stock Is A Good Buy

May 07

Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Apr 21

Organon Stock Is Still Worth A Look

Feb 24

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Feb 19

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

Feb 16

Organon: What I'm Looking For In This 8% Yield In 2024

Jan 03

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Dec 19

Organon: It's Darkest Before The Dawn

Nov 30

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

Nov 07

Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Nov 05

Organon: The Federal Reserve Black Swan (Rating Upgrade)

Oct 04

6% Yield And Significantly Undervalued: A Closer Look At Organon

Sep 10

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

Aug 10

Organon & Co.: A Tough Spot To Be In Right Now

Jul 16

Organon goes ex-dividend tomorrow

Feb 23

Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 19

Is There Anything Organic Or Interesting About Organon?

Feb 07

Organon goes ex-dividend tomorrow

Nov 09

Organon's (NYSE:OGN) Dividend Will Be $0.28

Nov 08

Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)

Nov 05

Opbrengsten en kosten

Hoe Organon geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NYSE:OGN Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	6,409	1,301	1,757	473
30 Jun 24	6,346	1,000	1,873	499
31 Mar 24	6,347	1,047	1,887	511
31 Dec 23	6,263	1,023	1,891	528
30 Sep 23	6,150	585	1,892	536
30 Jun 23	6,168	754	1,794	526
31 Mar 23	6,145	746	1,766	504
31 Dec 22	6,174	917	1,702	471
30 Sep 22	6,292	1,011	1,717	439
30 Jun 22	6,355	1,107	1,665	398
31 Mar 22	6,365	1,304	1,658	368
31 Dec 21	6,304	1,351	1,669	339
30 Sep 21	6,314	1,525	1,620	289
30 Jun 21	6,327	1,762	1,553	257
31 Mar 21	6,258	1,917	1,421	232
31 Dec 20	6,532	2,256	1,356	210
31 Dec 19	7,777	3,306	1,443	220
31 Dec 18	9,777	2,153	1,956	365
31 Dec 17	10,500	1,801	2,250	355

Kwaliteitswinsten: OGN heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (20.3%) OGN } zijn hoger dan vorig jaar (9.5%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van OGN is de afgelopen 5 jaar met 29.7% per jaar gedaald.

Versnelling van de groei: De winstgroei van OGN over het afgelopen jaar ( 122.4% ) overtreft het 5-jarig gemiddelde ( -29.7% per jaar).

Winst versus industrie: De winstgroei OGN over het afgelopen jaar ( 122.4% ) overtrof de Pharmaceuticals -sector 54.6%.

Rendement op eigen vermogen

Hoge ROE: Hoewel het rendement op eigen vermogen ( 263.89% ) van OGN uitstekend is, is deze metriek vertekend vanwege hun hoge schuldenniveau.

Organon Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Recent updates

Consensus EPS estimates increase by 20%

Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)

Organon & Co. Updates on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter dividend of US$0.28 announced

Organon & Co. Revises Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others.

Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion.

These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way

Organon & Co.: Cheap With Caveats

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price

Organon & Co. Affirms Revenue Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 16%

Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum

Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

Four Reasons Why Organon Stock Is A Good Buy

First quarter dividend of US$0.28 announced

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Organon & Co. Provides Earnings Guidance for the Year 2023

Organon & Co., Annual General Meeting, Jun 04, 2024

Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Organon & Co. to Report Q1, 2024 Results on May 02, 2024

CEO & Director exercised options and sold US$628k worth of stock

CEO & Director exercised options and sold US$729k worth of stock

Organon Stock Is Still Worth A Look

US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Fourth quarter dividend of US$0.28 announced

Full year 2023 earnings: EPS exceeds analyst expectations

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024

Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024

Investor sentiment improves as stock rises 18%

Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older

Organon: What I'm Looking For In This 8% Yield In 2024

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Organon: It's Darkest Before The Dawn

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 22%

Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd)

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Price target decreased by 13% to US$24.56

Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023

Organon: The Federal Reserve Black Swan (Rating Upgrade)

Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD)

Organon Announces First Real-World Observational Study of the JADA® System

6% Yield And Significantly Undervalued: A Closer Look At Organon

Organon Announces Two Leadership Appointments

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar

Price target decreased by 7.8% to US$28.38

Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023

Organon & Co.: A Tough Spot To Be In Right Now

Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator